Last $9.09 USD
Change Today +0.29 / 3.30%
Volume 707.3K
DYAX On Other Exchanges
As of 4:00 PM 07/23/14 All times are local (Market data is delayed by at least 15 minutes).

dyax corp (DYAX) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/26/14 - $10.99
52 Week Low
08/1/13 - $3.68
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for DYAX CORP (DYAX)

dyax corp (DYAX) Related Bloomberg News

View More Bloomberg News

dyax corp (DYAX) Related Businessweek News

No Related Businessweek News Found

dyax corp (DYAX) Details

Dyax Corp., a biopharmaceutical company, identifies, develops, and commercializes treatments for hereditary angioedema (HAE) and plasma kallikrein-mediated (PKM) angioedemas. The company offers KALBITOR for the treatment of acute attacks of HAE. It is developing DX-2930, a human monoclonal antibody inhibitor of plasma kallikrein, which would be a candidate to prophylactically treat HAE and other PKM disorders. The company distributes KALBITOR through a network of wholesale and specialty pharmacy arrangements. It has agreements with CVie Therapeutics for the development and commercialization of KALBITOR in the treatment of HAE and other angioedema indications in China; and Novellus Biopharma AG for the development and commercialization of KALBITOR for the treatment of HAE and other angioedema indications in Latin America, including Argentina, Brazil, Chile, Colombia, Mexico, and Venezuela. The company also has a strategic collaboration agreement with Sigma-Tau Rare Diseases S.A. to develop and commercialize subcutaneous ecallantide for the treatment of HAE and other therapeutic indications in Europe, North Africa, the Middle East, and Russia. Dyax Corp. was founded in 1989 and is headquartered in Burlington, Massachusetts.

120 Employees
Last Reported Date: 03/3/14
Founded in 1989

dyax corp (DYAX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $615.6K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $409.6K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $444.0K
Executive Vice President and General Counsel
Total Annual Compensation: $360.0K
Total Annual Compensation: $148.7K
Compensation as of Fiscal Year 2013.

dyax corp (DYAX) Key Developments

Dyax Corp. Announces Dosing of First Subject in Phase 1b Trial of DX-2930 in Patients with Hereditary Angioedema

Dyax Corp. announced dosing of the first subject in its Phase 1b clinical study of DX-2930 in hereditary angioedema (HAE) patients. The study is designed to evaluate the safety, tolerability, and pharmacokinetics of multiple subcutaneous administrations of DX-2930, an investigational fully human monoclonal antibody inhibitor of plasma kallikrein. Dyax, a biopharmaceutical company focused on HAE and other plasma-kallikrein-mediated disorders, is developing DX-2930 as a subcutaneous injection for prevention of HAE attacks. This Phase 1b trial is a multi-center, randomized, double-blind, placebo-controlled, multiple ascending dose study to assess the safety, tolerability and pharmacokinetics of DX-2930 in HAE patients. Approximately 18 subjects will be enrolled into three ascending dose cohorts (30 mg, 100 mg and 300 mg) of DX-2930 or placebo. There will be 4 active drug-treated subjects and 2 placebo-treated subjects per cohort. Each subject will receive two treatments with study drug, separated by two weeks, and undergo approximately 15 weeks of follow-up after the second dose.

Dyax Corp. Presents at Jefferies 2014 Global Healthcare Conference, Jun-02-2014 10:30 AM

Dyax Corp. Presents at Jefferies 2014 Global Healthcare Conference, Jun-02-2014 10:30 AM. Venue: Grand Hyatt, New York, New York, United States. Speakers: Gustav A. Christensen, Chief Executive Officer, President and Director.

Dyax Corp. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2014; Reiterates Financial Guidance for 2014

Dyax Corp. reported unaudited consolidated earnings results for the first quarter ended March 31, 2014. For the quarter, the company reported total revenues of USD 14.117 million compared to USD 12.040 million a year ago. Loss from operations was USD 3.026 million compared to USD 8.463 million a year ago. Net loss was USD 5.711 million compared to USD 11.193 million a year ago. Basic and diluted loss per share was USD 0.05 compared to USD 0.11 a year ago. The company reiterated its financial guidance for 2014. Top-line total revenue expected to be in the range of USD 53 million to USD 59 million, including KALBITOR net sales of USD 44 million to USD 49 million.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DYAX:US $9.09 USD +0.29

DYAX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
arGEN-X BV €8.47 EUR +0.11
BioCryst Pharmaceuticals Inc $12.12 USD +0.46
BioInvent International AB kr2.84 SEK -0.04
Pharming Group NV €0.45 EUR -0.021
XOMA Corp $4.15 USD +0.125
View Industry Companies

Industry Analysis


Industry Average

Valuation DYAX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 19.6x
Price/Book 11.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 16.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DYAX CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at